Recruiting
Phase 3

Erector Spinae vs. Intercostal

Sponsor:

George Washington University

Code:

NCT06810375

Conditions

Lung Cancers

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)

Intercostal nerve block

Study Details

Brief summary:

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Conditions

Lung Cancers

Study ID

NCT06810375

Start date

Mar 1, 2025

Status verified date

Apr, 2026

Completion date

Feb 28, 2029

Anticipated

Primary completion date

Feb 28, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Video assisted pulmonary resection, pleurodesis or decortication

Exclusion Criteria:

  • Allergy to local anesthetics
  • Patient undergoing bilateral surgery
  • Surgery is emergent as deemed by the principal investigator

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Preoperative Erector Spinae Block (ESB)(Bupivacaine)(Marcaine®)

active comparator: Intraoperative Intercostal Nerve Block (INB)(Liposomal Bupivacaine)(Exparel®)

Interventions

Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)

preoperative erector spinae block with bupivacaine (Marcaine®)

Intercostal nerve block

intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)

Primary outcome measure

  • Postoperative pain control assessment [ Time Frame: Up to 48 hours postoperatively ]
  • Morphine equivalent assessment [ Time Frame: Up to 72 hours postoperatively ]

Central Contacts and Locations

Central contacts

Eduard Shaykhinurov, MS

2022038960eshaykhinurov@mfa.gwu.edu

Locations

The George Washington University Hospital

Recruiting

Washington D.C., District of Columbia, United States, 20037

Contacts

Eduard Shaykhinurov

202-203-8960eshaykhinurov@mfa.gwu.edu

More Information

Sponsor

George Washington University

Last update posted

Apr 9, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by George Washington University on 2026-04-09.